{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:49:10Z","timestamp":1761821350602},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.coms.2013.09.009","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T10:21:17Z","timestamp":1385374877000},"page":"101-109","source":"Crossref","is-referenced-by-count":5,"title":["Management of Extraglandular Manifestations of Primary Sj\u00f6gren's Syndrome"],"prefix":"10.1016","volume":"26","author":[{"given":"Jason J.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Carsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coms.2013.09.009_bib1","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2174\/138920112802273254","article-title":"Current and future challenges in primary Sjogren\u2019s syndrome","volume":"13","author":"Vissink","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.coms.2013.09.009_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1759720X10363246","article-title":"Treating Sjogren\u2019s syndrome: insights for the clinician","volume":"2","author":"Vitale","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.coms.2013.09.009_bib3","series-title":"The Sjogren\u2019s book","first-page":"235","article-title":"Management of chronic musculoskeletal pain","author":"Chen","year":"2012"},{"key":"10.1016\/j.coms.2013.09.009_bib4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/rheumatology\/keq047","article-title":"Articular manifestations in primary Sjogren\u2019s syndrome: clinical significance and prognosis of 188 patients","volume":"49","author":"Fauchais","year":"2010","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1016\/j.coms.2013.09.009_bib5","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/096120339600500108","article-title":"Treatment of primary Sjogren's syndrome with hydroxchloroquine: a retrospective open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.coms.2013.09.009_bib6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.coms.2013.09.009_bib7","first-page":"555","article-title":"Methotrexate in primary Sjogren's syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coms.2013.09.009_bib8","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1007\/s00296-011-2036-2","article-title":"Rituximab treatment for Sjogren syndrome-associated non-Hodgkin\u2019s lymphoma: case series","volume":"32","author":"Covelli","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.coms.2013.09.009_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.berh.2012.01.012","article-title":"Sjogren\u2019s syndrome, the old and the new","volume":"26","author":"Peri","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.coms.2013.09.009_bib10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/ajcn\/82.4.887","article-title":"Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women","volume":"82","author":"Miljanovic","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.coms.2013.09.009_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.arcmed.2012.06.011","article-title":"Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis","volume":"45","author":"Lee","year":"2012","journal-title":"Arch Med Res"},{"key":"10.1016\/j.coms.2013.09.009_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2012.04374.x","article-title":"Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?","volume":"75","author":"Calder","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coms.2013.09.009_bib13","series-title":"The Sjogren\u2019s book","first-page":"271","article-title":"Vitamin D and Sjogren\u2019s syndrome","author":"Wilson","year":"2012"},{"key":"10.1016\/j.coms.2013.09.009_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/2042018812471070","article-title":"Vitamin D and rheumatoid arthritis","volume":"3","author":"Kostoglou-Athanassiou","year":"2012","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.coms.2013.09.009_bib15","first-page":"S82","article-title":"Fatigue in Sjogren\u2019s syndrome: relationship with fibromyalgia, clinical and biological features","volume":"28","author":"Priori","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coms.2013.09.009_bib16","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.sleep.2012.06.010","article-title":"Sleep disordered breathing in patients with primary Sj\u00f6gren's syndrome: a group controlled study","volume":"13","author":"Usmani","year":"2012","journal-title":"Sleep Med"},{"key":"10.1016\/j.coms.2013.09.009_bib17","series-title":"The Sjogren\u2019s book","first-page":"228","article-title":"Diagnosis and management of fatigue","author":"Mishra","year":"2012"},{"key":"10.1016\/j.coms.2013.09.009_bib18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.berh.2006.05.003","article-title":"Management of patients presenting with Sjogren\u2019s syndrome","volume":"20","author":"Venables","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.coms.2013.09.009_bib19","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren\u2019s syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coms.2013.09.009_bib20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomised, double-blind, palcebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coms.2013.09.009_bib21","first-page":"896","article-title":"A\u00a0double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coms.2013.09.009_bib22","doi-asserted-by":"crossref","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome-a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coms.2013.09.009_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/ard.2007.071563","article-title":"Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial","volume":"67","author":"Hartkamp","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coms.2013.09.009_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/acr.20022","article-title":"Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjogren's syndrome","volume":"62","author":"Virkki","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.coms.2013.09.009_bib25","series-title":"The Sjogren\u2019s book","first-page":"249","article-title":"Evaluation and management of the neurological manifestations of Sjogren\u2019s syndrome","author":"Mandel","year":"2012"},{"key":"10.1016\/j.coms.2013.09.009_bib26","first-page":"677","article-title":"Small fibre neuropathy: diagnostic approach and therapeutic issues, and its association with primary Sjogren\u2019s syndrome","volume":"31","author":"Sene","year":"2010","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.coms.2013.09.009_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2008.12.018","article-title":"Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren\u2019s syndrome","volume":"279","author":"Morozumi","year":"2009","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.coms.2013.09.009_bib28","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/acr.20495","article-title":"Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren\u2019s syndrome: a national multicentric retrospective study","volume":"63","author":"Rist","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coms.2013.09.009_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1017\/S0317167100006697","article-title":"Primary Sjogren\u2019s syndrome associated neuropathy","volume":"4","author":"Mellgren","year":"2007","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.coms.2013.09.009_bib30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/NRL.0b013e3181ebe59f","article-title":"Peripheral nervous system manifestations of Sjogren syndrome","volume":"16","author":"Birnbaum","year":"2010","journal-title":"Neurologist"},{"key":"10.1016\/j.coms.2013.09.009_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CND.0b013e3181c50513","article-title":"Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjogren\u2019s syndrome after rituximab therapy","volume":"11","author":"Botez","year":"2010","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.coms.2013.09.009_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren\u2019s syndrome with peripheral nervous system involvement: results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coms.2013.09.009_bib33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2147\/TCRM.S2712","article-title":"A\u00a041-year-old man with polyarthritis and severe autonomic neuropathy","volume":"4","author":"Bourcier","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.coms.2013.09.009_bib34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/hcr218","article-title":"White matter abnormalities in primary Sj\u00f6gren syndrome","volume":"105","author":"Akasbi","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.coms.2013.09.009_bib35","first-page":"69","article-title":"The Sj\u00f6gren's syndrome and multiple sclerosis: similarity and differences","volume":"112","author":"Pizova","year":"2012","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"10.1016\/j.coms.2013.09.009_bib36","series-title":"The Sjogren\u2019s book","first-page":"222","article-title":"Treatment of other sicca symptoms: dry skin","author":"Ray","year":"2012"},{"key":"10.1016\/j.coms.2013.09.009_bib37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.md.0000119465.24818.98","article-title":"Cutaneous vasculitis in primary Sjogren syndrome: classifications and clinical significance of 52 patients","volume":"83","author":"Ramos-Casals","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.coms.2013.09.009_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1590\/S0482-50042004000200013","article-title":"Primary Sjogren\u2019s syndrome with cutaneous vasculitis manifested as leg ulcerations","volume":"44","author":"Souza","year":"2004","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.coms.2013.09.009_bib39","first-page":"1032","article-title":"Dramatic response to intravenous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjogren\u2019s syndrome","volume":"25","author":"Durez","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coms.2013.09.009_bib40","series-title":"The Sjogren\u2019s book","first-page":"241","article-title":"Management of serious internal organ manifestations","author":"Small","year":"2012"},{"key":"10.1016\/j.coms.2013.09.009_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/rheumatology\/kes311","article-title":"Clincial pulmonary involvement in primary Sjogren\u2019s syndrome: prevalence, quality of life and mortality \u2013 a retrospective study based on registry data","volume":"52","author":"Palm","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.coms.2013.09.009_bib42","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.00980209","article-title":"Renal involvement in primary Sjogren\u2019s syndrome: a clinicopathologic study","volume":"4","author":"Maripuri","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.coms.2013.09.009_bib43","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coms.2013.09.009_bib44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patientswith rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Ann Rheum Dis"}],"container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369913001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369913001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T21:50:04Z","timestamp":1564869004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042369913001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1042369913001180"],"URL":"https:\/\/doi.org\/10.1016\/j.coms.2013.09.009","relation":{},"ISSN":["1042-3699"],"issn-type":[{"value":"1042-3699","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}